Long-term Follow-up Study to Evaluate Durability of Sustained Virologic Response (SVR) in Previous GSK3228836 Study Participants (B-Sure) - Trial NCT04954859
Access comprehensive clinical trial information for NCT04954859 through Pure Global AI's free database. This Phase 2 trial is sponsored by GlaxoSmithKline and is currently Not yet recruiting. The study focuses on Hepatitis B. Target enrollment is 450 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
GlaxoSmithKline
Timeline & Enrollment
Phase 2
Nov 30, 2021
Jan 25, 2029
Primary Outcome
Time from achieving SVR in previous GSK3228836 treatment study to loss of SVR (1st occurrence of either hepatitis B surface antigen or hepatitis B virus deoxyribonucleic acid [DNA] reversion, or 1st use of any rescue medication)-NA naïve participants,Time from NA cessation to the loss of SVR-NA controlled participants
Summary
This is a long-term follow-up study to assess durability of efficacy, as measured by SVR, in
 participants who have received prior treatment with GSK3228836 and achieved a complete or
 partial response. No further treatment with GSK3228836 will be administered in this study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04954859
Non-Device Trial